ALISO VIEJO, Calif., Oct. 15, 2007 (PRIME NEWSWIRE) -- SenoRx, Inc. (Nasdaq:SENO) today announced that it held its second symposium on October 8, 2007 for Contura(tm), its Multi-Lumen Balloon (MLB) Catheter, at the Annual Congress of the American College of Surgeons in New Orleans, Louisiana.
The event was attended by surgeons and radiation oncologists from 22 institutions across the United States. The presenters at the symposium were Douglas W. Arthur, M.D., Professor and Vice Chairman, Department of Radiation Oncology, Virginia Commonwealth University/Massey Cancer Center of Richmond, Virginia; Mark Alan Gittleman, M.D., Medical Director, Advanced Breast Care, Allentown, Pennsylvania; and Philip Z. Israel, M.D., Director, The Breast Center, Marietta, Georgia. Dr. Arthur outlined the study protocol, including the clinical endpoints for the Contura Registry Study, while, Dr. Gittleman and Dr. Israel described their early clinical experiences with Contura.
The study will evaluate the clinical outcomes of 500 patients for five years. Endpoints of the study will evaluate tumor recurrence rates, as well as cosmetic results. The company further hopes to demonstrate that the Contura design enables clinicians to increase the number of patients technically eligible for accelerated partial breast irradiation (APBI).
Commenting on his clinical experiences with Contura, Dr. Israel said, "I have been performing APBI for over five years. APBI has extensive clinical follow-up showing good results for local control of breast cancer when combined with lumpectomy. This new multi-lumen balloon catheter offers the potential to treat certain patients that are currently excluded from balloon brachytherapy due to the location of the lesion. Because the multi-lumen approach may address this issue, the Contura may offer protection to the skin and ribs of the patient by providing the opportunity to shape the dose and effectively radiate the tumor bed."
About Contura(tm)
SenoRx received 510(k) clearance from the U.S. Food and Drug Administration on May 23, 2007 for Contura(tm), its Multi-Lumen Balloon (MLB) Catheter for accelerated partial breast irradiation. Contura is one of a new class of devices which reduce treatment time to five days from six to eight weeks. SenoRx believes that the Contura multi-lumen balloon can play an important role in the shift from traditional whole breast radiation therapy to localized partial breast radiation therapy. Some patients who are presently candidates for balloon therapy are currently excluded because of the location of the lesion and their breast size. Contura's advanced multi-lumen design may address this issue for certain patients. In addition, the radiation balloon uses vacuum to remove excess fluid and to enhance conformance of often irregularly shaped lumpectomy cavity walls to the balloon surface in order to deliver precise radiation dosing through multiple radiation source lumens.
SenoRx has been granted three patents related either to the design or manufacturing of Contura. The first uses of Contura took place in late June 2007, at two clinical sites. SenoRx has subsequently expanded the use of Contura to additional clinical sites.
About SenoRx
SenoRx (Nasdaq:SENO), which completed its initial public offering of common stock in March 2007, develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis of breast cancer. SenoRx's field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. With 18 products having received FDA 510(k) clearance across the continuum of breast care, SenoRx is developing additional minimally invasive products for diagnosis and treatment of breast cancer. For more information, visit the company's website at www.senorx.com.
The SenoRx, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3605
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning SenoRx's future clinical development plans for Contura are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause SenoRx's actual results to differ materially from the statements contained herein. Information on potential risk factors that could affect SenoRx's business and its financial results are detailed in its prospectus dated March 29, 2007 and its most recent quarterly report on Form 10-Q, in each case as filed with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. SenoRx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.